| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.07 | 0.4 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | 0.46 | 0.4 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.036 | 0.4 |